PMID- 24062546
OWN - NLM
STAT- MEDLINE
DCOM- 20140728
LR  - 20151119
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 42
IP  - 1
DP  - 2014 Jan
TI  - Influence of antenatal magnesium sulfate application on cord blood levels of 
      brain-derived neurotrophic factor in premature infants.
PG  - 129-34
LID - 10.1515/jpm-2013-0137 [doi]
AB  - AIM: To investigate the influence of antenatal magnesium sulfate (MgSO4) 
      application on cord blood brain-derived neurotrophic factor (BDNF) levels - the 
      first-line neuroprotection for preventing cerebral palsy in prematurely born 
      infants. SUBJECTS AND METHODS: A randomized controlled trial was conducted by 
      observing 72 pregnant women who were divided into three groups: group I (preterm 
      pregnancy with MgSO4), group II (preterm pregnancy without MgSO4), and group III 
      (full-term pregnancy as control group). Groups I and II were selected by block 
      permutation randomization on subjects. Inclusion criteria consisted of preterm 
      pregnancy at 34 weeks of gestation or less who were in labor or having planned 
      terminations and receiving antenatal corticosteroids. Exclusion criteria 
      consisted of previous complications caused by MgSO4, previous history of 
      antenatal MgSO4 application in the current pregnancy infant was born before 4 h 
      administration of MgSO4 or unborn more than 72 h after maximum course of 
      antenatal MgSO4 of 24 h, prolonged antenatal MgSO4 treatment (>24 h), refusal to 
      participate, and emergent adverse events during the study. Group I was given 
      intravenous MgSO4; initial dose was 4 g, which was maintained at 1 g/h up to 
      maximum of 24 h. Meanwhile, groups II and III were not given any special 
      treatment. BDNF was examined by ELISA by taking 5 mL cord blood sample shortly 
      after birth. The result was statistically measured by ANOVA. RESULTS: The cord 
      blood BDNF levels in premature infants with antenatal MgSO4 was significantly 
      higher than in premature infants without antenatal MgSO4 (11,568 vs. 5027 pg/mL, 
      P=0.000). Moreover, the result was statistically comparable to full-term infants 
      (11,568 vs. 13,300 pg/mL, P=0.085). CONCLUSION: The application of antenatal 
      MgSO4 in preterm delivery increased cord blood BDNF levels, which could have a 
      potential role on fetal neuroprotection. Further investigation is needed.
FAU - Bachnas, Muhammad Adrianes
AU  - Bachnas MA
FAU - Mose, Johanes Cornelius
AU  - Mose JC
FAU - Effendi, Jusuf Sulaeman
AU  - Effendi JS
FAU - Andonotopo, Wiku
AU  - Andonotopo W
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 7487-88-9 (Magnesium Sulfate)
SB  - IM
MH  - Administration, Intravenous
MH  - Adult
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cerebral Palsy/blood/*prevention & control
MH  - Drug Administration Schedule
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fetal Blood/*metabolism
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Infant, Premature, Diseases/blood/*prevention & control
MH  - Magnesium Sulfate/*therapeutic use
MH  - Neuroprotective Agents/*therapeutic use
MH  - Pre-Eclampsia/drug therapy
MH  - Pregnancy
MH  - Premature Birth
MH  - Prenatal Care/*methods
EDAT- 2013/09/26 06:00
MHDA- 2014/07/30 06:00
CRDT- 2013/09/25 06:00
PHST- 2013/06/13 00:00 [received]
PHST- 2013/08/14 00:00 [accepted]
PHST- 2013/09/25 06:00 [entrez]
PHST- 2013/09/26 06:00 [pubmed]
PHST- 2014/07/30 06:00 [medline]
AID - /j/jpme.ahead-of-print/jpm-2013-0137/jpm-2013-0137.xml [pii]
AID - 10.1515/jpm-2013-0137 [doi]
PST - ppublish
SO  - J Perinat Med. 2014 Jan;42(1):129-34. doi: 10.1515/jpm-2013-0137.